Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus

1997/09/01 by Marc C. Hochberg · 65 citations
Medicine · #Systemic Lupus Erythematosus Research #Lymphoma Diagnosis and Treatment #Monoclonal and Polyclonal Antibodies Research

paper · doi:10.1002/art.1780400928

Cited by

• Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus
• Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis
• Neutrophil Heterogeneity Identifies an Association of LAMP1 With Proliferative Lupus Nephritis
• Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
• Immunosuppressive therapy in lupus‐ and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty‐three cases
• Network analysis of associations between serum interferon‐α activity, autoantibodies, and clinical features in systemic lupus erythematosus
• Identification of an Anti–Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis
• The use of laboratory tests in the diagnosis of SLE
• Endoplasmic reticulum stress sensor IRE1α propels neutrophil hyperactivity in lupus
• Defective B cell tolerance checkpoints in systemic lupus erythematosus
• B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-λ in Systemic Lupus Erythematosus
• A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
• Epigenetic attenuation of interferon signaling drives aging-related improvements in systemic lupus
• Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus
• Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritis
• Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study
• Genetic risk factors and clinical manifestations of systemic lupus erythematosus: Large‐scale analysis of genetic predisposition and disease subtypes
• A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
• Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study
• A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus
• Systemic lupus erythematosus in Native sub-Saharan Africans: A systematic review and meta-analysis
• Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE
• Agreement between parent- and self-report of executive functioning in childhood-onset systemic lupus erythematosus: implications for clinical practice
• Applying Genetic Risk Score to Improve Risk Assessment of New‐Onset Lupus Nephritis in Systemic Lupus Erythematosus: A Large‐Scale Prospective Cohort Study
• A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
• Toll-like receptor expression and functional behavior in platelets from patients with systemic lupus erythematosus
• SELECTION OF ANTI-NUCLEAR ANTIGEN (ANA) REACTIVE B CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS
• Xist ribonucleoproteins promote female sex-biased autoimmunity
• Placental malperfusion and angiogenesis‐related proteins are associated with small‐for‐gestational‐age in systemic lupus erythematosus
• Hair Fluorescence Spectroscopy as a Non-Invasive Biomarker for Diagnosis and Remission Monitoring in Systemic Lupus Erythematosus
• Machine Learning-Based Identification of Novel Exosome-Derived Metabolic Biomarkers for the Diagnosis of Systemic Lupus Erythematosus and Differentiation of Renal Involvement
• Achievement of lupus low disease activity state (LLDAS) in a New Zealand cohort: a prospective study of ethnic differences in outcomes
• Subclinical atherosclerosis is associated with future cardiovascular events in lupus patients at apparent low cardiovascular risk
• Neutrophil FcγRI expression as a determinant of oxidative responses in human blood
• The long-term outcome of 93 patients with proliferative lupus nephritis
• Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients With Systemic Lupus Erythematosus
• Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis
• Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population
• Native T1 and T2 mapping by CMR in lupus myocarditis: Disease recognition and response to treatment
• Evaluation of a Pediatric-Adult Dyad Care Model for Transitioning Youth With Childhood-Onset Systemic Lupus Erythematosus
• A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. [europepmc]
• Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. [europepmc]
• Understanding the epidemiology and progression of systemic lupus erythematosus. [europepmc]
• MicroRNA in autoimmunity and autoimmune diseases. [europepmc]
• Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. [europepmc]
• Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. [europepmc]
• A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. [europepmc]
• Novel evidence-based systemic lupus erythematosus responder index. [europepmc]
• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. [europepmc]
• A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. [europepmc]
• Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. [europepmc]
• Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. [europepmc]
• A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. [europepmc]
• Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. [europepmc]
• Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. [europepmc]
• Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. [europepmc]
• Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. [europepmc]
• Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. [europepmc]
• Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. [europepmc]
• Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. [europepmc]
• 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. [europepmc]
• Global epidemiology of systemic lupus erythematosus. [europepmc]
• Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. [europepmc]
• B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. [europepmc]
• Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. [europepmc]